Abstract:Abstract Background Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive disease with poor survival, and platinum-etoposide chemotherapy is indicated as the mainstay of treatment. In this study, we compared the efficacy and safety between the cisplatin plus etoposide (EP) and carboplatin plus etoposide (EC) regimens. Methods A total of 1305 patients with previously untreated ES-SCLC were included in this study. Data from five trials were collected from the public database Project Data Sphere. Survival analysis and adverse events (AEs) analysis were conducted. Results Of the 1305 patients, 800 received the EC regimen whereas 505 received the EP regimen as their front-line treatment. Overall, the median progression-free survival (PFS) and the median overall survival (OS) were 172 and 289 days, respectively. The EP and EC treatment groups did not have significantly different PFS or OS. After adjusting for age, sex, body mass index (BMI) and Eastern Cooperative Oncology Group (ECOG) performance status (PS), the EP regimen was independently associated with better PFS (hazard ratio [HR] = 0.76, 95% CI = 0.63–0.92, p = 0.0041) and OS (HR = 0.79, 95% CI = 0.64–0.97, p = 0.0220) among patients who were overweight and obese (BMI ≥ 25 kg/m 2 ). In the safety analysis, patients who received the EC treatment experienced significantly more grade ≥ 3 AEs ( n = 599, 74.9%) than those who received the EP treatment ( n = 337, 66.7%; p = 0.002). Furthermore, the EC regimen was associated with a higher risk of grade 3–4 neutropaenia ( p = 0.001), thrombocytopaenia ( p < 0.001) and hyponatraemia ( p = 0.036), whereas the EP regimen was associated with a higher risk of grade 3–4 vomiting ( p = 0.021). Conclusions In summary, this study presented the efficacy and safety of the EC and EP regimens in patients with ES-SCLC in the first-line setting. Patients who are overweight and obese benefit more from the EP regimen than EC regimen. Approaches to define the optimal chemotherapy regimen in different BMI subgroups are needed.

Efficacy and safety of irinotecan/platinum versus etoposide/platinum chemotherapy for extensive-stage small cell lung cancer

Irinotecan/cisplatin Versus Etoposide/cisplatin for Patients with Extensive Stage Small Cell Lung Cancer: A Systematic Review

A Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated Extensive-Stage Small Cell Lung Cancer

Efficacy and Safety of PD-L1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study.

Irinotecan Plus Cisplatin Compared with Etoposide Plus Cisplatin for Small Cell Lung Cancer: a Randomized Clinical Trial.

Efficacy and safety of immune checkpoint inhibitors plus platinum-etoposide vs. platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer: a systematic review and a meta-analysis

Clinical comparative analysis of EP regimen vs sequential IP as the first-line treatment for extensive-disease small cell lung cancer

Comparison of vinorelbine, ifosfamide and cisplatin (NIP) and etoposide and cisplatin (EP) for treatment of advanced combined small cell lung cancer (cSCLC) patients: a retrospective study.

A Meta Analysis of Cisplatin Combined with Irinotecan or Etoposide in the Treatment of Extensive-Disease Small Cell Lung Cancer

Comparative Study of Iobaplatin and Cisplatin Combined with Etoposide for Advanced Small Cell Lung Cancer

Cisplatin Plus Etoposide Versus Other Platin-Based Regimens For Patients With Extensive Small-Cell Lung Cancer: A Systematic Review And Meta-Analysis Of Randomised, Controlled Trials

Preliminary Results of Randomized Phase II Study of Etoposide Plus Lobaplatin or Etoposide Plus Cisplatin with Concurrent Thoracic Radiotherapy in the Treatment of Limited-Stage Small Cell Lung Cancer.

[Randomized clinical trial of IEP and EP regimens in the treatment of patients with small cell lung cancer].

The Study of Concurrent Chemoradiation with EP Regimen in Limited Stage Small Cell Lung Cancer

Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial.

Randomized Controlled Trial of Lobaplatin Plus Etoposide Vs. Cisplatin Plus Etoposide As First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer.

Etoposide plus lobaplatin versus etoposide plus cisplatin for patients with extensive stage small cell lung cancer:A Meta -analysis

Topotecan plus Platinum-Based Chemotherapy versus Etoposide plus Platinum-Based Chemotherapy for Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Safety of irinotecan/cisplatin versus etoposide/cisplatin for patients with extensive-stage small-cell lung cancer: a metaanalysis.

Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis

Etoposide-cisplatin alternating with vinorelbine-cisplatin versus etoposide-cisplatin alone in patients with extensive disease combined with small cell lung cancer.